H.C. Wainwright analyst Ed Arce lowered the firm’s price target on 89bio to $25 from $27 on recent dilution, while affirming a Buy rating on the shares. The firm notes 89bio is due to report the highly-anticipated top-line results from its Phase 2b ENLIVEN study of pegozafermin for the treatment NASH this quarter. H.C. Wainwright remains "highly confident in a robustly positive top-line readout" of ENLIVEN within the next 11 calendar days.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ETNB:
- SVB Securities remains bullish on 89bio’s ENLIVEN study readout
- 89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- 89bio reports Q4 EPS (48c), consensus (69c)
- 89bio presents new analysis of data from Phase 2 ENTRIGUE trial of pegozafermin
- 89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology
